{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T04:42:56Z","timestamp":1777869776292,"version":"3.51.4"},"reference-count":52,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,30]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>While modern anticancer therapies have significantly improved survival in patients with cancer, their success is often hindered by unintended side effects and toxicities, particularly to the kidneys. Many conventional chemotherapeutic agents, despite their efficacy, exert nephrotoxic effects that can result in short- and long-term adverse kidney outcomes. This review critically examines the renal implications of non-platinum alkylating agents and other less commonly grouped cytotoxic drugs based on available literature. Nephrotoxicity remains a frequent and often dose-limiting challenge in patients with cancer, even with preventive measures. As such, there is a growing need to identify predictive biomarkers and develop targeted kidney-protective strategies. An understanding of these agents\u2019 kidney toxicity profiles is critical to maximize the oncologic benefit while preserving kidney function in this vulnerable population.<\/jats:p>","DOI":"10.1093\/ndt\/gfaf220","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T12:12:35Z","timestamp":1760703155000},"page":"828-838","source":"Crossref","is-referenced-by-count":1,"title":["Nephrotoxicity of conventional chemotherapeutics: part II\u2014non-platinum agents and miscellaneous nephrotoxic drugs"],"prefix":"10.1093","volume":"41","author":[{"given":"Adam","family":"Kelly","sequence":"first","affiliation":[{"name":"Medical College of Wisconsin Division of Nephrology, Department of Medicine, , Milwaukee, WI ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sourabh","family":"Sharma","sequence":"additional","affiliation":[{"name":"Vardhman Mahavir Medical College and Safdarjung Hospital Department of Nephrology, , New Delhi ,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Mamlouk","sequence":"additional","affiliation":[{"name":"The University of Texas, MD Anderson Cancer Center , Houston, TX ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Hassanein","sequence":"additional","affiliation":[{"name":"Specialized Universal Network of Oncology Center , Alexandria ,","place":["Egypt"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raad","family":"Chowdhury","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Boston, Massachusetts; Dana Farber Cancer Institute, Boston, Massachusetts; and Harvard Medical School Division of Renal Medicine, Department of Medicine, , Boston, MA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5747-2151","authenticated-orcid":false,"given":"Shruti","family":"Gupta","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Boston, Massachusetts; Dana Farber Cancer Institute, Boston, Massachusetts; and Harvard Medical School Division of Renal Medicine, Department of Medicine, , Boston, MA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huong","family":"Truong","sequence":"additional","affiliation":[{"name":"Associate Director, Medical Science Liason \u2013 Hematology, Loxo@Lilly , West Hartford, CT ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9087-9730","authenticated-orcid":false,"given":"Marco","family":"Bonilla","sequence":"additional","affiliation":[{"name":"University of Chicago Section of Nephrology, Department of Medicine, , Chicago, IL ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kartik","family":"Kalra","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Geisinger Medical Center , Danville, PA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rimda","family":"Wanchoo","sequence":"additional","affiliation":[{"name":"Division of Kidney Diseases and Hypertension, Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell , Great Neck, NY ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanazul","family":"Pariswala","sequence":"additional","affiliation":[{"name":"Dallas Renal Group, Methodist Dallas Medical Center , Dallas, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna-Eve","family":"Turcotte","sequence":"additional","affiliation":[{"name":"CIUSSS de l\u2019Estrie \u2013 Centre Hospitalier Universitaire de Sherbrooke Department of Nephrology, , Sherbrooke, Qu\u00e9bec ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ishaan","family":"Zaveri","sequence":"additional","affiliation":[{"name":"The Cooper Union Department of Mechanical Engineering, , New York City, NY ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl","family":"Dernell","sequence":"additional","affiliation":[{"name":"Medical College of Wisconsin Department of Pathology, , Milwaukee, WI ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"Medical College of Wisconsin Division of Nephrology, Department of Medicine, , Milwaukee, WI ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maulinkumar","family":"Patel","sequence":"additional","affiliation":[{"name":"The University of Texas Health Science Center at Houston , Houston, TX ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvia S","family":"Eskander","sequence":"additional","affiliation":[{"name":"Northeastern University , Boston, MA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prakash","family":"Gudsoorkar","sequence":"additional","affiliation":[{"name":"University of Cincinnati College of Medicine Division of Nephrology, Department of Medicine, , OH ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1578-0524","authenticated-orcid":false,"given":"Kenar D","family":"Jhaveri","sequence":"additional","affiliation":[{"name":"Division of Kidney Diseases and Hypertension, Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell , Great Neck, NY ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A","family":"Perazella","sequence":"additional","affiliation":[{"name":"Yale University School of Medicine Section of Nephrology, Department of Medicine, , New Haven, CT ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4976-9104","authenticated-orcid":false,"given":"Paul E","family":"Hanna","sequence":"additional","affiliation":[{"name":"Medical College of Wisconsin Division of Nephrology, Department of Medicine, , Milwaukee, WI ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"key":"2026043010390935500_bib1","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1002\/cncr.22904","article-title":"Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study","volume-title":"Cancer","author":"Launay-Vacher","year":"2007"},{"key":"2026043010390935500_bib2","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1093\/jnci\/djy167","article-title":"Acute kidney injury in patients receiving systemic treatment for cancer: A population-based cohort study","volume-title":"J Natl Cancer Inst","author":"Kitchlu","year":"2019"},{"key":"2026043010390935500_bib3","article-title":"Ifosfamide. [Updated 2024 Jan 9]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing","author":"Gangireddy","year":"2025"},{"key":"2026043010390935500_bib4","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1023\/A:1007561727948","article-title":"New insights into the pharmacokinetics and metabolism of (R, S)-Ifosfamide in cancer patients using a population pharmacokinetic-metabolism model","volume":"17","author":"Di Marco","year":"2000","journal-title":"Pharm Res"},{"key":"2026043010390935500_bib5","doi-asserted-by":"publisher","first-page":"368","DOI":"10.6004\/jadpro.2020.11.4.4","article-title":"Risk factors for ifosfamide-related encephalopathy in adult cancer patients: an integrative review","volume":"11","author":"Brink","year":"2020","journal-title":"J Adv Pract Oncol"},{"key":"2026043010390935500_bib6","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1200\/JCO.1991.9.12.2177","article-title":"Long-term follow-up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors: an international society of pediatric oncology report","volume":"9","author":"Suarez","year":"1991","journal-title":"J Clin Oncol"},{"key":"2026043010390935500_bib7","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1007\/s13730-023-00829-z","article-title":"A case of ifosfamide-induced acute kidney injury, Fanconi syndrome, and nephrogenic diabetes insipidus","volume":"13","author":"Hoang","year":"2024","journal-title":"CEN Case Rep"},{"key":"2026043010390935500_bib8","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1016\/j.freeradbiomed.2007.08.020","article-title":"Ifosfamide induces acute renal failure via inhibition of the thioredoxin reductase activity","volume":"43","author":"Zhang","year":"2007","journal-title":"Free Radical Biol Med"},{"key":"2026043010390935500_bib9","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1016\/j.ejca.2012.03.009","article-title":"Long term renal toxicity of ifosfamide in adult patients\u20135year data","volume-title":"Eur J Cancer","author":"Farry","year":"2012"},{"key":"2026043010390935500_bib10","doi-asserted-by":"crossref","first-page":"922","DOI":"10.2215\/CJN.09980912","article-title":"Long-term nephrotoxicity in adult survivors of childhood cancer","volume":"8","author":"Dekkers","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026043010390935500_bib11","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1093\/ckj\/sfz183","article-title":"Ifosfamide nephrotoxicity in adult patients","volume":"13","author":"Ensergueix","year":"2020","journal-title":"Clin Kidney J"},{"key":"2026043010390935500_bib12","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.trsl.2007.02.001","article-title":"The effect of N-acetylcysteine on ifosfamide-induced nephrotoxicity: in vitro studies in renal tubular cells","volume":"150","author":"Chen","year":"2007","journal-title":"Transl Res"},{"key":"2026043010390935500_bib13","doi-asserted-by":"publisher","first-page":"e13518","DOI":"10.1200\/JCO.2022.40.16_suppl.e13518","article-title":"International consensus guideline for anticancer drug dosing in kidney dysfunction (ADDIKD): a standardized approach to assessing kidney function in cancer patients and its application to anticancer drug dosing","volume":"40","author":"Sandhu","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026043010390935500_bib14","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1046\/j.1523-1755.2002.00279.x","article-title":"Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency","volume":"61","author":"Haubitz","year":"2002","journal-title":"Kidney Int"},{"key":"2026043010390935500_bib15","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1093\/ndt\/gfp657","article-title":"Hyponatraemia induced by low-dose intravenous pulse cyclophosphamide","volume":"25","author":"Lee","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"2026043010390935500_bib16","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1001\/archinte.1985.00360030196034","article-title":"Water intoxication following moderate-dose intravenous cyclophosphamide","volume":"145","author":"Bressler","year":"1985","journal-title":"Arch Intern Med"},{"key":"2026043010390935500_bib17","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s40268-012-0001-5","article-title":"Pharmacokinetics and excretion of 14C-bendamustine in patients with relapsed or refractory malignancy","volume":"13","author":"Dubbelman","year":"2013","journal-title":"Drugs R D"},{"key":"2026043010390935500_bib18","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/bmt.2015.257","article-title":"Bendamustine-based conditioning for non-Hodgkin lymphoma autologous transplantation: an increasing risk of renal toxicity","volume":"51","author":"Garciaz","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"2026043010390935500_bib19","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/ajh.25077","article-title":"Bendamustine-based conditioning prior to autologous stem cell transplantation (ASCT): results of a French multicenter study of 474 patients from LYmphoma Study Association (LYSA) centers","volume":"93","author":"Chantepie","year":"2018","journal-title":"Am J Hematol"},{"key":"2026043010390935500_bib20","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1053\/j.ajkd.2016.07.037","article-title":"Bendamustine-induced nephrogenic diabetes insipidus in a patient with AL amyloidosis","volume":"69","author":"Uwumugambi","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"2026043010390935500_bib21","first-page":"36","article-title":"Acquired Gitelman syndrome secondary to bendamustine use","volume":"101","author":"Rogers","year":"2018","journal-title":"R I Med J (2013)"},{"key":"2026043010390935500_bib22","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s00280-010-1254-8","article-title":"Bendamustine pharmacokinetic profile and exposure-response relationships in patients with indolent non-Hodgkin\u2019s lymphoma","volume":"66","author":"Owen","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026043010390935500_bib23","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/j.1365-2125.2010.03638.x","article-title":"Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy","volume":"69","author":"Nath","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"2026043010390935500_bib24","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1053\/j.ajkd.2004.09.015","article-title":"Acute renal insufficiency after high-dose melphalan in patients with primary systemic amyloidosis during stem cell transplantation","volume":"45","author":"Leung","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"2026043010390935500_bib25","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1038\/s41409-024-02292-5","article-title":"Acute kidney injury during autologous stem cell transplantation in light chain amyloidosis with kidney involvement and their impact on prognosis","volume":"59","author":"Xu","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"2026043010390935500_bib26","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1093\/ndt\/gfab189","article-title":"Predictors and outcomes of acute kidney injury during autologous stem cell transplantation in AL amyloidosis","volume":"37","author":"Nader","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"2026043010390935500_bib27","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/1097-0142(19850101)55:1<44::AID-CNCR2820550107>3.0.CO;2-B","article-title":"Syndrome of inappropriate antidiuretic hormone secretion. A complication of high-dose intravenous melphalan","volume":"55","author":"Greenbaum-Lefkoe","year":"1985","journal-title":"Cancer"},{"key":"2026043010390935500_bib28","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1200\/JCO.2015.65.0044","article-title":"International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment","volume":"34","author":"Dimopoulos","year":"2016","journal-title":"J Clin Oncol"},{"key":"2026043010390935500_bib29","author":"ZANOSAR\u00ae (Streptozocin Sterile Powder)"},{"key":"2026043010390935500_bib30","doi-asserted-by":"publisher","first-page":"108","DOI":"10.7326\/0003-4819-79-1-108","article-title":"pancreatic islet cell carcinoma","volume":"79","author":"Broder","year":"1973","journal-title":"Ann Intern Med"},{"key":"2026043010390935500_bib31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-023-35850-w","article-title":"Streptozotocin induces renal proximal tubular injury through p53 signaling activation","volume":"13","author":"Nakai","year":"2023","journal-title":"Sci Rep"},{"key":"2026043010390935500_bib32","article-title":"YONDELIS (trabectedin) for injection, for intravenous use","author":"FDA"},{"key":"2026043010390935500_bib33","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1200\/JCO.2004.05.210","article-title":"Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients","volume":"22","author":"Yovine","year":"2004","journal-title":"J Clin Oncol"},{"key":"2026043010390935500_bib34","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s10637-011-9662-0","article-title":"A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials","volume":"30","author":"Le Cesne","year":"2012","journal-title":"Invest New Drugs"},{"key":"2026043010390935500_bib35","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1007\/s00280-012-1864-4","article-title":"A comprehensive safety analysis confirms rhabdomyolysis as an uncommon adverse reaction in patients treated with trabectedin","volume":"69","author":"Grosso","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026043010390935500_bib36","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1177\/1078155209352821","article-title":"Fatal hepatic and renal toxicity as a complication of trabectedin therapy for radiation-induced sarcoma","volume":"16","author":"Pick","year":"2010","journal-title":"J Oncol Pharm Pract"},{"key":"2026043010390935500_bib37","first-page":"5017","article-title":"Pharmacokinetics of mitomycin C in humans","volume":"43","author":"den Hartigh","year":"1983","journal-title":"Cancer Res"},{"key":"2026043010390935500_bib38","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1053\/j.ajkd.2015.02.340","article-title":"Thrombotic microangiopathy, cancer, and cancer drugs","volume":"66","author":"Izzedine","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"2026043010390935500_bib39","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1200\/JCO.1989.7.6.781","article-title":"Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry","volume":"7","author":"Lesesne","year":"1989","journal-title":"J Clin Oncol"},{"key":"2026043010390935500_bib40","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/1097-0142(19850101)55:1<47::AID-CNCR2820550108>3.0.CO;2-#","article-title":"Renal complications of mitomycin C therapy with special reference to the total dose","volume":"55","author":"Valavaara","year":"1985","journal-title":"Cancer"},{"key":"2026043010390935500_bib41","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/j.2042-7158.2012.01567.x","article-title":"Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems","volume":"65","author":"Tacar","year":"2013","journal-title":"J Pharm Pharmacol"},{"key":"2026043010390935500_bib42","doi-asserted-by":"publisher","first-page":"419","DOI":"10.2165\/00003088-200342050-00002","article-title":"Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies","volume":"42","author":"Gabizon","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"2026043010390935500_bib43","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1007\/s00280-004-0825-y","article-title":"Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study","volume":"54","author":"Mross","year":"2004","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026043010390935500_bib44","doi-asserted-by":"publisher","first-page":"111308","DOI":"10.1016\/j.biopha.2021.111308","article-title":"Apigenin ameliorates doxorubicin-induced renal injury via inhibition of oxidative stress and inflammation","volume":"137","author":"Wu","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"2026043010390935500_bib45","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1177\/1078155218798157","article-title":"Renal toxicity with liposomal doxorubicin in metastatic breast cancer","volume":"25","author":"Yemm","year":"2019","journal-title":"J Oncol Pharm Pract"},{"key":"2026043010390935500_bib46","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/ki.2013.408","article-title":"Pegylated liposomal doxorubicin and renal thrombotic microangiopathy: an under-recognized complication of prolonged treatment for ovarian cancer","volume":"85","author":"Shavit","year":"2014","journal-title":"Kidney Int"},{"key":"2026043010390935500_bib47","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s00280-007-0535-3","article-title":"Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas","volume":"61","author":"Kroschinsky","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026043010390935500_bib48","doi-asserted-by":"publisher","first-page":"e27038","DOI":"10.1002\/PBC.27038","article-title":"Acute kidney injury after high dose etoposide phosphate: a retrospective study in children receiving an allogeneic hematopoetic stem cell transplantation","volume":"65","author":"Barnoud","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"2026043010390935500_bib49","doi-asserted-by":"publisher","first-page":"e26669","DOI":"10.1002\/PBC.26669","article-title":"Unexpected acute renal injury after high-dose etoposide phosphate and total body irradiation in children undergoing hematopoietic stem cell transplantation","volume":"64","author":"Cordero","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"2026043010390935500_bib50","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1136\/jcp.2003.013979","article-title":"Atypical haemolytic uraemic syndrome as a complication of induction chemotherapy for acute lymphoblastic leukaemia","volume":"57","author":"Chandra","year":"2004","journal-title":"J Clin Pathol"},{"key":"2026043010390935500_bib51","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1097\/01.mph.0000165130.21539.a3","article-title":"Vincristine-induced urinary bladder paralysis","volume":"27","author":"El Hayek","year":"2005","journal-title":"J Pediatr Hematol Oncol"},{"key":"2026043010390935500_bib52","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/BF00313556","article-title":"Syndrome of inappropriate secretion of antidiuretic hormone caused by vincristine therapy: a case report of the neuropathology","volume":"229","author":"Tomiwa","year":"1983","journal-title":"J Neurol"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfaf220\/64738928\/gfaf220.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/41\/5\/828\/64738928\/gfaf220.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/41\/5\/828\/64738928\/gfaf220.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T14:39:16Z","timestamp":1777559956000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/41\/5\/828\/8292648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":52,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,10,17]]},"published-print":{"date-parts":[[2026,4,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfaf220","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2025,10,17]]}}}